{
    "info": {
        "nct_id": "NCT03665922",
        "official_title": "Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer",
        "inclusion_criteria": "1. Men ≥ 18 years of age scheduled to undergo radical prostatectomy as standard of care for a diagnosis of prostate adenocarcinoma.\n2. Subjects willing to take oral placebo or BroccoMax® pills (4 capsules twice daily after breakfast and dinner) on a daily basis for 4 weeks prior to prostatectomy. Subjects have the ability to swallow BroccoMax® or placebo pills.\n3. Subjects in good health per investigator evaluation with liver enzyme and blood count values within the following ranges:\n\n   White blood cells ≥ 3,000/mL Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN) Aspartate Aminotransferase (AST (SGOT))/ Alanine Aminotransferase (ALT (SGPT)) ≤ 2.5 x ULN Blood Urea Nitrogen (BUN) and serum creatinine ≤ 1.5 x ULN\n4. Subjects willing to abstain from dietary sources of glucosinolates and isothiocyanates (see Appendix) for the duration of the study (4 weeks)\n5. Subjects must be fully informed of the investigational nature of this study and must sign a written informed consent in accordance within institutional and regulatory guidelines\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 90 Years",
        "exclusion_criteria": "1. Subjects ineligible to undergo prostatectomy due to co-morbidities.\n2. Subjects with a second malignancy or any other cancer at least 3 years following definitive treatment with no evidence of disease, except for adequately treated basal cell or squamous cell skin cancer.\n3. Subjects with malabsorption issues or gastrointestinal ailments than can interfere with the ability to adequately absorb SFN.\n4. Subjects with prior or concurrent androgen deprivation therapy with Luteinizing hormone-releasing hormone (LHRH) agonist or antagonists\n5. Subjects taking any other investigational agent, dietary supplement or herbal supplement or participating in clinical studies involving investigational agents\n6. Subjects with clinically significant comorbid diseases including active infection, uncontrolled angina, New York Heart Assoc. (NYHA) class III or IV heart failure, uncontrolled or uncontrollable hypertension, severe diabetes with complications, chronic liver disease.\n7. Subjects with prior history of known intolerance or allergic reactions attributed to cruciferous vegetables or specific fillers used in the placebo.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 90 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 90 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subjects must be fully informed of the investigational nature of this study and must sign a written informed consent in accordance within institutional and regulatory guidelines",
            "criterions": [
                {
                    "exact_snippets": "Subjects must be fully informed of the investigational nature of this study",
                    "criterion": "subject information about investigational nature of study",
                    "requirements": [
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must sign a written informed consent in accordance within institutional and regulatory guidelines",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "compliance with guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Men ≥ 18 years of age scheduled to undergo radical prostatectomy as standard of care for a diagnosis of prostate adenocarcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Men",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "scheduled to undergo radical prostatectomy as standard of care",
                    "criterion": "planned procedure",
                    "requirements": [
                        {
                            "requirement_type": "procedure",
                            "expected_value": "radical prostatectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of prostate adenocarcinoma",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "disease",
                            "expected_value": "prostate adenocarcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects willing to take oral placebo or BroccoMax® pills (4 capsules twice daily after breakfast and dinner) on a daily basis for 4 weeks prior to prostatectomy. Subjects have the ability to swallow BroccoMax® or placebo pills.",
            "criterions": [
                {
                    "exact_snippets": "Subjects willing to take oral placebo or BroccoMax® pills (4 capsules twice daily after breakfast and dinner) on a daily basis for 4 weeks prior to prostatectomy",
                    "criterion": "willingness to take study medication",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medication type",
                            "expected_value": [
                                "oral placebo",
                                "BroccoMax® pills"
                            ]
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "capsules twice daily"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after breakfast and dinner"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "weeks prior to prostatectomy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects have the ability to swallow BroccoMax® or placebo pills",
                    "criterion": "ability to swallow study medication",
                    "requirements": [
                        {
                            "requirement_type": "ability to swallow",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medication type",
                            "expected_value": [
                                "BroccoMax®",
                                "placebo pills"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects in good health per investigator evaluation with liver enzyme and blood count values within the following ranges:",
            "criterions": [
                {
                    "exact_snippets": "Subjects in good health per investigator evaluation",
                    "criterion": "general health status",
                    "requirements": [
                        {
                            "requirement_type": "health status",
                            "expected_value": "good (per investigator evaluation)"
                        }
                    ]
                },
                {
                    "exact_snippets": "liver enzyme ... values within the following ranges",
                    "criterion": "liver enzyme values",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within specified ranges"
                        }
                    ]
                },
                {
                    "exact_snippets": "blood count values within the following ranges",
                    "criterion": "blood count values",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within specified ranges"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects willing to abstain from dietary sources of glucosinolates and isothiocyanates (see Appendix) for the duration of the study (4 weeks)",
            "criterions": [
                {
                    "exact_snippets": "Subjects willing to abstain from dietary sources of glucosinolates and isothiocyanates ... for the duration of the study (4 weeks)",
                    "criterion": "dietary intake of glucosinolates and isothiocyanates",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "White blood cells ≥ 3,000/mL Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN) Aspartate Aminotransferase (AST (SGOT))/ Alanine Aminotransferase (ALT (SGPT)) ≤ 2.5 x ULN Blood Urea Nitrogen (BUN) and serum creatinine ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "White blood cells ≥ 3,000/mL",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3000,
                                "unit": "mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Aspartate Aminotransferase (AST (SGOT))/ Alanine Aminotransferase (ALT (SGPT)) ≤ 2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) and alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Blood Urea Nitrogen (BUN) and serum creatinine ≤ 1.5 x ULN",
                    "criterion": "blood urea nitrogen (BUN) and serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "7. Subjects with prior history of known intolerance or allergic reactions attributed to cruciferous vegetables or specific fillers used in the placebo.",
            "criterions": [
                {
                    "exact_snippets": "prior history of known intolerance or allergic reactions attributed to cruciferous vegetables",
                    "criterion": "intolerance or allergic reactions to cruciferous vegetables",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of known intolerance or allergic reactions attributed to...specific fillers used in the placebo",
                    "criterion": "intolerance or allergic reactions to specific fillers used in the placebo",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subjects taking any other investigational agent, dietary supplement or herbal supplement or participating in clinical studies involving investigational agents",
            "criterions": [
                {
                    "exact_snippets": "Subjects taking any other investigational agent",
                    "criterion": "use of other investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "dietary supplement or herbal supplement",
                    "criterion": "use of dietary supplement or herbal supplement",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participating in clinical studies involving investigational agents",
                    "criterion": "participation in clinical studies involving investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects with malabsorption issues or gastrointestinal ailments than can interfere with the ability to adequately absorb SFN.",
            "criterions": [
                {
                    "exact_snippets": "malabsorption issues",
                    "criterion": "malabsorption issues",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal ailments than can interfere with the ability to adequately absorb SFN",
                    "criterion": "gastrointestinal ailments interfering with SFN absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with SFN absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Subjects with clinically significant comorbid diseases including active infection, uncontrolled angina, New York Heart Assoc. (NYHA) class III or IV heart failure, uncontrolled or uncontrollable hypertension, severe diabetes with complications, chronic liver disease.",
            "criterions": [
                {
                    "exact_snippets": "clinically significant comorbid diseases including active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant comorbid diseases including ... uncontrolled angina",
                    "criterion": "uncontrolled angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Assoc. (NYHA) class III or IV heart failure",
                    "criterion": "heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or uncontrollable hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": [
                                "uncontrolled",
                                "uncontrollable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "severe diabetes with complications",
                    "criterion": "diabetes with complications",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "complications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic liver disease",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects with a second malignancy or any other cancer at least 3 years following definitive treatment with no evidence of disease, except for adequately treated basal cell or squamous cell skin cancer.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with a second malignancy or any other cancer at least 3 years following definitive treatment with no evidence of disease",
                    "criterion": "second malignancy or any other cancer",
                    "requirements": [
                        {
                            "requirement_type": "time since definitive treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except for adequately treated basal cell or squamous cell skin cancer",
                    "criterion": "basal cell or squamous cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Subjects ineligible to undergo prostatectomy due to co-morbidities.",
            "criterions": [
                {
                    "exact_snippets": "ineligible to undergo prostatectomy due to co-morbidities",
                    "criterion": "eligibility for prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "reason for ineligibility",
                            "expected_value": "co-morbidities"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with prior or concurrent androgen deprivation therapy with Luteinizing hormone-releasing hormone (LHRH) agonist or antagonists",
            "criterions": [
                {
                    "exact_snippets": "prior or concurrent androgen deprivation therapy with Luteinizing hormone-releasing hormone (LHRH) agonist or antagonists",
                    "criterion": "androgen deprivation therapy with LHRH agonist or antagonists",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}